Vinorelbine-associated myelopathy in a patient who previously received paclitaxel: A case report

Medical Oncology

Volumn 18, Issue 1, 2001, Pages 95-97

  Han, Ji Youn ^a   Choi, Byung Gil ^a   Song, Dae Heon ^a   Ahn, Jae Geun ^a   Yoon, Jeong Seob ^a   Lee, Kyung Shik ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Myelopathy; Vinorelbine

Indexed keywords

NAVELBINE; PACLITAXEL; VINCA ALKALOID;

ADULT; ARTICLE; CASE REPORT; DRUG INFUSION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINAL CORD DISEASE; SYMPTOMATOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PACLITAXEL; SPINAL CORD; SPINAL CORD DISEASES; VINBLASTINE;

EID: 0034812051     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:18:1:95     Document Type: Article

References (6)

1. A summary of vinorelbine (Navelbine) safety data from North American clinical trials
2. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: Phase II study
3. Vinorelbine neurotoxicity: Clinical and neurophysiological findings in 23 patients
4. Neurologic complications of chemotherapy
5. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: A phase II study
6. Severe neurotoxicity from vinorelbine-paclitaxel combinations